BC
MCID: BRS047
MIFTS: 100

Breast Cancer (BC)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Immune diseases, Rare diseases, Reproductive diseases, Skin diseases

Aliases & Classifications for Breast Cancer

MalaCards integrated aliases for Breast Cancer:

Name: Breast Cancer 58 12 77 26 76 38 13 56 6 44 15 3 64
Breast Carcinoma 12 26 76 30 56 6 15 17 74
Breast Cancer, Familial 58 77 54 26 74
Breast Cancer, Lobular 58 39 30 6
Male Breast Cancer 12 54 44 15
Breast Cancer, Susceptibility to 58 30 6
Malignant Neoplasm of Breast 12 26 74
Breast Cancer, Early-Onset 58 30 6
Carcinoma of Male Breast 30 6 74
Mammary Carcinoma 12 76 15
Breast Cancer, Protection Against 58 6
Malignant Neoplasm of Male Breast 12 74
Invasive Ductal Breast Carcinoma 56 74
Breast Cancer, Invasive Ductal 58 39
Hereditary Breast Carcinoma 54 60
Familial Breast Carcinoma 54 60
Familial Cancer of Breast 30 6
Breast Lobular Carcinoma 12 15
Hereditary Breast Cancer 54 60
Familial Breast Cancer 54 60
Primary Breast Cancer 12 15
Male Breast Carcinoma 54 17
Breast Cancer, Male 58 54
Mammary Cancer 12 26
Mammary Tumor 12 56
Breast Cancer, Early-Onset, Susceptibility to 58
Breast Cancer, Male, Susceptibility to 58
Primary Malignant Neoplasm of Breast 74
Susceptibility to Breast Cancer 17
Malignant Tumor of the Breast 12
Breast Cancer Susceptibility 58
Breast Cancer, Familial Male 30
Breast Cancer Familial Male 76
Malignant Tumor of Breast 26
Cancer, Breast, Familial 41
Lobular Breast Carcinoma 17
Animal Mammary Neoplasms 74
Neoplasm of Male Breast 12
Heritable Breast Cancer 54
Cancer, Breast, Lobular 41
Breast Cancer, Somatic 58
Breast Cancer Familial 76
Breast Neoplasms, Male 45
Genetic Breast Cancer 54
Breast Male Carcinoma 56
Breast Cancer in Men 54
Carcinoma of Breast 12
Mammary Neoplasms 74
Mammary Neoplasm 12
Cancer of Breast 26
Breast Neoplasms 45
Breast Neoplasm 17
Cancer, Breast 41
Breast Tumor 12
Bc 76

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant
somatic mutation

Miscellaneous:
genetic heterogeneity


HPO:

33
breast cancer:
Inheritance heterogeneous autosomal dominant inheritance


Classifications:



Summaries for Breast Cancer

NIH Rare Diseases : 54 Familial breast cancer is a cluster of breast cancer within a family. Most cases of breast cancer occur sporadically in people with little to no family history of the condition. Approximately 5-10% of breast cancer is considered "hereditary" and is thought to be caused by an inherited predisposition to breast cancer that is passed down through a family in an autosomal dominant manner. In some of these families, the underlying genetic cause is not known; however, many of these cases are caused by changes (mutations) in the BRCA1, BRCA2, PTEN, TP53, CDH1, or STK11 genes (which are each associated with a unique hereditary cancer syndrome). Additional genes, such as CHEK2, BRIP1, RAD51, and ATM, are associated with breast and/or gynecologic cancers in some cases. About 15-20% of women diagnosed with breast cancer have a significant family history of breast cancer (two or more first-degree or second-degree relatives with breast cancer) but have no identifiable mutation in a gene known to cause a hereditary predisposition to breast cancer. These clusters of breast cancer are likely due to a combination of gene(s) and other shared factors such as environment and lifestyle.High-risk cancer screening and other preventative measures such as chemoprevention and/or prophylactic surgeries are typically recommended in women who have an increased risk for breast cancer based on their personal and/or family histories.

MalaCards based summary : Breast Cancer, also known as breast carcinoma, is related to bilateral breast cancer and sporadic breast cancer, and has symptoms including pain, lameness, animal and pelvic pain. An important gene associated with Breast Cancer is BRCA2 (BRCA2 DNA Repair Associated), and among its related pathways/superpathways are Breast cancer and MicroRNAs in cancer. The drugs Abraxane and Afinitor have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and bone, and related phenotypes are breast carcinoma and Decreased viability

Disease Ontology : 12 A thoracic cancer that originates in the mammary gland.

Genetics Home Reference : 26 Breast cancer is a disease in which certain cells in the breast become abnormal and multiply uncontrollably to form a tumor. Although breast cancer is much more common in women, this form of cancer can also develop in men. In both women and men, the most common form of breast cancer begins in cells lining the milk ducts (ductal cancer). In women, cancer can also develop in the glands that produce milk (lobular cancer). Most men have little or no lobular tissue, so lobular cancer in men is very rare.

OMIM : 58 Breast cancer (referring to mammary carcinoma, not mammary sarcoma) is histopathologically and almost certainly etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. (114480)

MedlinePlus : 44 Breast cancer affects one in eight women during their lives. No one knows why some women get breast cancer, but there are many risk factors. Risks that you cannot change include Age - the risk rises as you get older Genes - two genes, BRCA1 and BRCA2, greatly increase the risk. Women who have family members with breast or ovarian cancer may wish to be tested for the genes. Personal factors - beginning periods before age 12 or going through menopause after age 55 Other risks include obesity, using hormone replacement therapy (also called menopausal hormone therapy), taking birth control pills, drinking alcohol, not having children or having your first child after age 35, and having dense breasts. Symptoms of breast cancer may include a lump in the breast, a change in size or shape of the breast, and discharge from a nipple. Breast self-exams and mammography can help find breast cancer early, when it is most treatable. One possible treatment is surgery. It could be a lumpectomy or a mastectomy. Other treatments include radiation therapy, chemotherapy, hormone therapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. Men can have breast cancer, too, but it is rare. NIH: National Cancer Institute

CDC : 3 Learn what breast cancer is, who is at high risk, and about symptoms, mammograms, diagnosis, and treatment for breast cancer.

Novus Biologicals : 57 Breast cancer is a malignant tumor that originates from breast tissue cells. Although most breast cancers initiate in the cells that line the breast ducts, some begin in the breast lobules and other tissues. As with all cancers, there is a genetic and environmental component of developing breast cancer. Women with defects in the BRCA1 and BRCA2 genes have up to an 80% chance of getting breast cancer. Research has also found that defects in the ErbB-2 gene lead to increased levels of the protein cyclin D1. Cyclin D1 then activates CDK4, which causes proliferation of cellular division. Blocking CDK4 activity may lead to effective breast cancer treatments.

UniProtKB/Swiss-Prot : 76 Breast cancer: A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.

PubMed Health : 64 About breast cancer: Being diagnosed with breast cancer often comes as a shock at first, and makes people feel very frightened and anxious. Having cancer can really turn your life upside down for a while. It helps to know that if you get breast cancer for the first time and it hasn’t spread far, there’s a good chance that treatment can lead to full recovery. There are also many support services that help people in everyday life, to return to work and cope emotionally with breast cancer.

Wikipedia : 77 Breast cancer is cancer that develops from breast tissue. Signs of breast cancer may include a lump in... more...

Related Diseases for Breast Cancer

Diseases in the Breast Cancer family:

Inflammatory Breast Carcinoma Sporadic Breast Cancer
Breast Carcinoma in Situ

Diseases related to Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1336)
# Related Disease Score Top Affiliating Genes
1 bilateral breast cancer 35.7 ATM BRCA1 BRCA2 CHEK2 ERBB2 PALB2
2 sporadic breast cancer 35.6 ATM BARD1 BRCA1 BRCA2 CHEK2 ERBB2
3 female breast cancer 35.5 ATM BRCA1 BRCA2 ERBB2 ESR1 PALB2
4 estrogen-receptor positive breast cancer 35.4 AKT1 ERBB2 ESR1 PIK3CA TP53
5 synchronous bilateral breast carcinoma 35.1 ATM BRCA1 BRCA2 ESR1 TP53
6 estrogen-receptor negative breast cancer 35.0 BRCA1 ERBB2 ESR1
7 glycogen-rich clear cell breast carcinoma 34.9 BRCA1 BRCA2 ESR1 TP53
8 inflammatory breast carcinoma 34.8 CDH1 ERBB2 ESR1
9 hereditary breast ovarian cancer syndrome 34.1 ATM BARD1 BRCA1 BRCA2 BRIP1 CHEK2
10 li-fraumeni syndrome 34.1 TP53 CHEK2 BRCA2 BRCA1 ATM
11 ovarian cancer 33.8 TP53 PPM1D PIK3CA PALB2 ESR1 ERBB2
12 adenocarcinoma 33.7 AKT1 CDH1 ERBB2 PIK3CA TP53
13 breast medullary carcinoma 33.2 BRCA1 ERBB2 ESR1
14 ductal carcinoma in situ 33.1 AKT1 BRCA1 BRCA2 CDH1 ERBB2 ESR1
15 li-fraumeni syndrome 2 33.0 CHEK2 TP53
16 luminal breast carcinoma 33.0 AKT1 ERBB2 ESR1
17 breast squamous cell carcinoma 33.0 ERBB2 PIK3CA TP53
18 prostate cancer 33.0 TP53 PIK3CA ESR1 ERBB2 CHEK2 CDH1
19 in situ carcinoma 32.9 TP53 ESR1 ERBB2 CDH1 BRCA1
20 lung cancer 32.9 AKT1 ATM CASP8 CDH1 CHEK2 ERBB2
21 lipid-rich carcinoma 32.9 CDH1 ERBB2 ESR1
22 colorectal cancer 32.9 AKT1 BRCA1 BRCA2 BRIP1 CASP8 CDH1
23 breast disease 32.9 BRCA1 BRCA2 ERBB2 ESR1 TP53
24 endometrial cancer 32.8 TP53 PIK3CA ESR1 ERBB2 CDH1 BRCA2
25 rare adenocarcinoma of the breast 32.7 PIK3CA AKT1 TP53
26 comedo carcinoma 32.7 ERBB2 ESR1
27 breast scirrhous carcinoma 32.5 ERBB2 ESR1
28 fanconi anemia, complementation group a 32.2 RAD51 PALB2 BRIP1 BRCA2 BRCA1 ATM
29 esophageal cancer 32.2 AKT1 CASP8 CDH1 CHEK2 ERBB2 PIK3CA
30 pancreatic cancer 32.2 TP53 PIK3CA PALB2 ERBB2 CDH1 BRCA2
31 breast reconstruction 32.2 BRCA1 BRCA2
32 ataxia-telangiectasia 32.2 ATM BRCA1 CHEK2 TP53
33 cervical cancer 32.1 AKT1 CASP8 CDH1 ERBB2 PIK3CA TP53
34 ovarian cancer 1 32.0 AKT1 BRCA1 BRCA2 CDH1 ERBB2 PIK3CA
35 squamous cell carcinoma 31.9 AKT1 CDH1 CHEK2 ERBB2 PIK3CA TP53
36 breast ductal carcinoma 31.9 TP53 RAD54L ESR1 ERBB2 CDH1 BRCA1
37 wilms tumor 1 31.8 BRCA2 CHEK2 ERBB2 ESR1 TP53
38 adenoid cystic carcinoma 31.8 TP53 PIK3CA ERBB2 CHEK2 CDH1 ATM
39 lung cancer susceptibility 3 31.7 AKT1 CASP8 CDH1 ERBB2 PIK3CA TP53
40 lymphoma, non-hodgkin, familial 31.7 ATM CASP8 PIK3CA RAD54L TP53
41 glioblastoma 31.7 AKT1 BRCA2 ERBB2 PIK3CA TP53
42 breast adenocarcinoma 31.7 AKT1 CASP8 ERBB2 ESR1 PIK3CA TP53
43 xeroderma pigmentosum, variant type 31.6 XRCC3 TP53 RAD54L RAD51 ATM
44 breast carcinoma in situ 31.6 BRCA1 BRCA2 ERBB2 ESR1 TP53
45 carcinosarcoma 31.6 ERBB2 PIK3CA TP53
46 endometrial adenocarcinoma 31.6 AKT1 ERBB2 ESR1 TP53
47 endocrine gland cancer 31.6 AKT1 BRCA1 BRCA2 CDH1 ERBB2 ESR1
48 cholangiocarcinoma 31.5 AKT1 CDH1 ERBB2 PIK3CA TP53
49 meningioma, familial 31.5 AKT1 CDH1 ESR1 TP53
50 mutagen sensitivity 31.5 XRCC3 TP53 BRCA2 BRCA1

Graphical network of the top 20 diseases related to Breast Cancer:



Diseases related to Breast Cancer

Symptoms & Phenotypes for Breast Cancer

Human phenotypes related to Breast Cancer:

33
# Description HPO Frequency HPO Source Accession
1 breast carcinoma 33 HP:0003002

Symptoms via clinical synopsis from OMIM:

58
Neoplasia:
breast carcinoma

Clinical features from OMIM:

114480

UMLS symptoms related to Breast Cancer:


pain, lameness, animal, pelvic pain

GenomeRNAi Phenotypes related to Breast Cancer according to GeneCards Suite gene sharing:

27 (show all 37)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.94 PIK3CA
2 Decreased viability GR00221-A-1 10.94 AKT1 ESR1 PIK3CA
3 Decreased viability GR00221-A-2 10.94 AKT1 BRCA1 CHEK2 ESR1 PIK3CA
4 Decreased viability GR00221-A-3 10.94 AKT1 BRCA1 CHEK2 ATM ERBB2
5 Decreased viability GR00221-A-4 10.94 AKT1 CHEK2 ESR1 PIK3CA ATM ERBB2
6 Decreased viability GR00301-A 10.94 BRCA1
7 Decreased viability GR00342-S-2 10.94 CHEK2
8 Decreased viability GR00402-S-2 10.94 AKT1 BRCA1 CHEK2 ESR1 PIK3CA ATM
9 Decreased homologous recombination repair frequency GR00151-A-1 10.77 BARD1 BRCA1 RAD51
10 Decreased homologous recombination repair frequency GR00151-A-2 10.77 BRCA1 RAD51
11 Decreased homologous recombination repair frequency GR00236-A-1 10.77 BARD1 BRCA1 BRCA2 PALB2 RAD51
12 Decreased homologous recombination repair frequency GR00236-A-2 10.77 ATM BARD1 BRCA1 BRCA2 PALB2 RAD51
13 Decreased homologous recombination repair frequency GR00236-A-3 10.77 BARD1 BRCA1 BRCA2 PALB2 RAD51
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-1 10.41 CHEK2
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-112 10.41 CHEK2
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-142 10.41 CHEK2
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.41 ERBB2
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 10.41 CHEK2
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-17 10.41 CASP8
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.41 AKT1
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.41 PIK3CA
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 10.41 CHEK2
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-48 10.41 CHEK2
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.41 PIK3CA
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.41 AKT1 CASP8 CHEK2 ERBB2 PIK3CA
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.41 CHEK2
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 10.41 ERBB2
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 10.41 CASP8
29 Decreased viability in esophageal squamous lineage GR00235-A 10.11 BRCA1 BRCA2 CDH1 CHEK2 ERBB2 ESR1
30 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.02 AKT1 ATM BARD1 BRCA1 BRCA2 CASP8
31 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.02 AKT1 ATM BARD1 BRCA1 BRCA2 CASP8
32 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.97 ATM BARD1 BRCA1 BRCA2 BRIP1 CASP8
33 Decreased viability with cisplatin GR00101-A-4 9.72 BARD1 BRCA1 BRCA2 BRIP1 RAD51
34 Decreased viability with paclitaxel GR00179-A-1 9.65 ERBB2 PHB PPM1D
35 Decreased viability with paclitaxel GR00179-A-2 9.65 PPM1D
36 Decreased viability with paclitaxel GR00179-A-3 9.65 PPM1D
37 Synthetic lethal with cisplatin GR00101-A-1 9.43 BARD1 BRCA1 BRCA2 BRIP1 RAD51 XRCC3

MGI Mouse Phenotypes related to Breast Cancer:

47 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.44 AKT1 ATM BARD1 BRCA1 BRCA2 BRIP1
2 endocrine/exocrine gland MP:0005379 10.35 AKT1 ATM BRCA1 BRCA2 BRIP1 CASP8
3 growth/size/body region MP:0005378 10.33 AKT1 ATM BARD1 BRCA1 BRCA2 CASP8
4 embryo MP:0005380 10.31 AKT1 ATM BARD1 BRCA1 BRCA2 CASP8
5 homeostasis/metabolism MP:0005376 10.28 AKT1 ATM BRCA1 BRCA2 BRIP1 CASP8
6 cardiovascular system MP:0005385 10.22 AKT1 ATM BRCA1 CASP8 CDH1 ERBB2
7 mortality/aging MP:0010768 10.21 AKT1 ATM BARD1 BRCA1 BRCA2 CASP8
8 immune system MP:0005387 10.18 AKT1 ATM BRCA1 BRCA2 CASP8 CDH1
9 hematopoietic system MP:0005397 10.17 AKT1 ATM BRCA1 BRCA2 CASP8 CHEK2
10 integument MP:0010771 10.13 AKT1 ATM BRCA1 BRCA2 CASP8 CDH1
11 neoplasm MP:0002006 10.06 AKT1 ATM BARD1 BRCA1 BRCA2 BRIP1
12 nervous system MP:0003631 9.77 AKT1 ATM BARD1 BRCA1 BRCA2 BRIP1
13 reproductive system MP:0005389 9.44 AKT1 ATM BRCA1 BRCA2 BRIP1 CDH1

Drugs & Therapeutics for Breast Cancer

PubMedHealth treatment related to Breast Cancer: 64

The treatment options always depend on the type and size of the tumor, where it has spread to (if it has spread), the patient’s general health, as well as their personal preferences. Breast cancer can be treated with surgery, radiation and medication. Different treatment approaches are often combined.The standard treatment is to try to surgically remove as much of the tumor as possible. Neighboring lymph nodes are sometimes also removed. If the tumor is small, women are often faced with a decision: Should they keep the breast or have it completely removed? Nowadays many women can have surgery that allows them to keep the breast (breast-conserving surgery). But sometimes the entire breast needs to be removed (mastectomy) to make sure that all of the tumor tissue has gone.Chemotherapy (treatment with medication) is sometimes used to shrink larger tumors before surgery and make it easier to operate on them. This kind of treatment is called “neoadjuvant chemotherapy.”Chemotherapy is sometimes used after surgery too. Women who have a hormone-sensitive tumor may have anti-hormonal therapy. This aims to slow down tumor growth.After breast-conserving surgery the surrounding tissue is exposed to radiation, if possible, so that any remaining tumor cells can be destroyed. This is sometimes necessary after a mastectomy as well. Radiotherapy is also commonly used if the tumor cannot be surgically removed.The different types of treatment can be very difficult to go through and sometimes have very severe side effects or cause other medical problems. The side effects vary depending on the kind of treatment, but they are often easy to treat. The treatment of side effects is part of what is known as supportive care.Before deciding on whether to have a particular treatment, there is usually enough time to get information from your doctor about the possible benefits and the expected side effects, and to talk with your family or other people who are close to you. You have the right to seek a second opinion from another doctor or to decide not to have a treatment.

FDA approved drugs:

(show all 48)
# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Abraxane 19 50 PACLITAXEL Celgene October 2012
2
Afinitor 19 50 EVEROLIMUS Novartis March 2009
3
Aredia 19 50 PAMIDRONATE DISODIUM Chiron August 1996
4
Arimidex 19 50 ANASTROZOLE AstraZeneca January 1996
5
Aromasin Tablets 19 50 EXEMESTANE Pharmacia & Upjohn October 21. 1999
6
Bosulif 19 50 BOSUTINIB MONOHYDRATE Pfizer September 2012
7
CEA-Scan 19 Immunomedics April 1996
8
Degarelix 19 50 degarelix Ferring Pharmaceuticals December of 2008
9
Ellence 19 50 EPIRUBICIN HYDROCHLORIDE Pharmacia & Upjohn September 1999
10
Evista 19 50 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
11
Faslodex 19 50 FULVESTRANT AstraZeneca April 2002
12
Femara 19 50 LETROZOLE Novartis January 2001
13
Gazyva 19 50 OBINUTUZUMAB Genentech October of 2013
14
Gemzar 19 50 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
15
Halaven 19 50 ERIBULIN MESYLATE Eisai November 2010
16
Herceptin 19 50 TRASTUZUMAB Genentech October 1998
17
Ibrance 19 50 PALBOCICLIB Pfizer February 2015
18
Inform HER-2/neu breast cancer test 19 Oncor January 1998
19
Iressa 19 50 GEFITINIB AstraZeneca May 2003
20
Ixempra 19 50 IXABEPILONE Bristol-Myers Squibb October 2007
21
Kadcyla 19 50 ADO-TRASTUZUMAB EMTANSINE Genentech February 2013
22
Lupron Depot 19 50 LEUPROLIDE ACETATE TAP Pharmaceuticals/ Abbott Laboratories July 1997/ January 1996
23
Miraluma Test 19 TECHNETIUM TC-99M SESTAMIBI KIT DuPont Merck Pharmaceutical Company May 1997
24
Mozobil 19 50 PLERIXAFOR Genzyme December 2008
25
Neulasta 19 PEGFILGRASTIM Amgen January 2002
26
Neutroval 19 tbo-filgrastim Teva Pharmaceutical August 2012
27
Nolvadex 19 50 TAMOXIFEN CITRATE AstraZeneca October 1998
28
Perjeta 19 50 PERTUZUMAB Genentech June 2012
29
Premarin 19 ESTROGENS CONJUGATED Wyeth July of 2003
30
Self-examination breast pad 19 Inventive Products on December 22, 1995
31
Sprycel 19 50 DASATINIB Bristol-Myers Squibb June 2006
32
Sylatron 19 50 PEGINTERFERON ALFA-2B Merck April 2011
33
Synribo 19 50 OMACETAXINE MEPESUCCINATE Teva Pharmaceutical October 2012
34
Taxol 19 50 PACLITAXEL Bristol-Myers Squibb August 1997
35
Taxotere 19 50 DOCETAXEL Rhone Poulenc Rorer May 1996
36
Tykerb 19 50 LAPATINIB DITOSYLATE GlaxoSmithKline March 2007
37
Velcade 19 50 BORTEZOMIB Millennium Pharmaceuticals May 2003
38
Xeloda 19 50 CAPECITABINE Roche April 1998/ May 2001
39
Xgeva 19 50 DENOSUMAB Amgen June 2013/ November 2010
40
Yervoy 19 50 IPILIMUMAB Bristol-Myers Squibb March 2011
41
Zoladex 19 50 GOSERELIN ACETATE AstraZeneca January 1996
42
Zometa 19 50 ZOLEDRONIC ACID Novartis August 2001/ February 2002
43
Daliresp 19 ROFLUMILAST Forest Pharmaceuticals February 2011
44
Nucala 19 MEPOLIZUMAB GlaxoSmithKline November 2015
45
Opsumit 19 MACITENTAN Actelion Pharmaceuticals October 2013
46
Remodulin 19 TREPROSTINIL United Therapeutics May 2002
47
Rhinocort Aqua Nasal Spray 19 BUDESONIDE AstraZeneca October 1999
48
Xolair 19 OMALIZUMAB Genentech June 2003

Drugs for Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1268)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33069-62-4 36314
2
Zoledronic Acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 118072-93-8 68740
3
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 112809-51-5 3902
4
Toremifene Approved, Investigational Phase 4,Phase 3,Phase 2 89778-26-7 3005573
5
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 439-14-5 3016
6
Methylene blue Approved, Investigational Phase 4,Phase 2,Not Applicable 61-73-4
7
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 120511-73-1 2187
8
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56420-45-2 41867
9
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 41575-94-4 38904 10339178 498142
10
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
11
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
12
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
13
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
14
Povidone Approved Phase 4,Phase 2 9003-39-8
15
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
16
Povidone-iodine Approved Phase 4,Phase 3 25655-41-8
17
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7553-56-2 807
18
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 55-56-1 2713 9552079
19
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 107868-30-4 60198
20
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 10540-29-1 2733526
21
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
22
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
23
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 170729-80-3 151165 6918365
24
Fosaprepitant Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 172673-20-0 219090
25
Ondansetron Approved Phase 4,Phase 3,Phase 2,Not Applicable 99614-02-5 4595
26
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 7439-89-6, 15438-31-0 23925 27284
27
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
28
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
29
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2 302-25-0
30
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2 2921-57-5
31
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 124-94-7 31307
32
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-83-0 5994
33
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-28-2 5757
34
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 2 71-58-9
35
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28014-46-2
36
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 437-38-7 3345
37
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-27-2 5288826
38
Ketamine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 6740-88-1 3821
39
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2180-92-9, 38396-39-3 2474
40
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 51-43-4 5816
41
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 329-65-7 838
42
Levobupivacaine Approved, Investigational Phase 4,Not Applicable 27262-47-1 92253
43
Tramadol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 27203-92-5 33741
44
Acetylcholine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 51-84-3 187
45
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 114977-28-5 148124
46
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 159351-69-6 6442177 70789204
47
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
48
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,